Medicus Pharma Ltd.
MDCXHealthcareNASDAQDrug Manufacturers - General · Last scanned Oct 26, 2026
Scan Results
Daily timeframeMedicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. The $3.6M market capitalization puts MDCX squarely in micro-cap range for its industry. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Market Cap
$3.6M
Beta
-0.30
P/E (TTM)
—
P/E (Fwd)
-0.10
EPS (TTM)
$-119.00
EPS (Fwd)
$-24.00
ROE
-7446.1%
ROA
-110.7%
Cash
$15.2M
Total Debt
$21.6M
Free CF
-$16.2M
52W Change
-97.9%
Annual Financials
Cash vs Debt
Where MDCX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MDCX finished 82.86% below its 150-day moving average ($15.46) and 89.88% below its 200-day moving average ($26.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MDCX overbought or oversold?
At the October 20, 2026 close, MDCX's RSI(14) was 14.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Medicus Pharma Ltd. carries $21.6M in total debt against $15.2M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$16.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -7446.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Medicus Pharma Ltd. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MDCX.